Table 1. Demographic and Clinicopathologic Characteristics of Primary Cohort for Sustained Response Duration Analysis.
| Characteristic | Primary Cohort (n = 2403) |
Validation Cohort (n = 331) |
|---|---|---|
| Age, median (range), y | 57 (18-75) | 56.2 (18-75) |
| Sex, male/female, No. | 2190/213 | 309/22 |
| Hepatitis B virus, yes/no, No. | 2000/403 | 290/41 |
| Hepatitis C virus, yes/no, No. | 49/2354 | 6/325 |
| Nonalcoholic fatty liver disease, yes/no, No. | 252/2151 | 37/294 |
| Alcoholic liver disease, yes/no, No. | 134/2269 | 21/310 |
| α-Fetoprotein, median (range), ng/mL | 803 (0-138 400) | 822 (0-138 400) |
| Carbohydrate antigen 19-9, median (range), U/ml | 10.0 (0.5-40.0) | 15.0 (0.5-40.0) |
| γ-Glutamyltransferase, median (range), U/L | 192.0 (10.0-950.0) | 181.0 (10.0-950.0) |
| Alkaline phosphatase, median (range), U/L | 70.0 (36.0-856.0) | 87.5 (40.0-850.0) |
| Aspartate aminotransferase, median (range), U/L | 42.0 (8.0-260.0) | 40.0 (8.0-210.0) |
| Alanine transaminase, median (range), U/L | 45.0 (10.0-314.0) | 42.0 (10.0-324.0) |
| Albumin, median (range), g/L | 36.0 (29.0-47.0) | 35.0 (29.0-45.0) |
| Total bilirubin, median (range), mg/dL | 0.9 (0.4-1.8) | 0.8 (0.4-1.9) |
| Prothrombin time, median (range), s | 12.0 (10.0-16.0) | 12.2 (10.4-16.5) |
| White blood cell count, median (range), per μL | 5000 (4000-10 000) | 5000 (4000-10 000) |
| Hemoglobin, median (range), g/dL | 12.2 (11.0-15.0) | 12.0 (11.0-15.0) |
| Platelet count, median (range), ×103/μL | 110.0 (80.0-440.0) | 110.0 (90.0-440.0) |
| Creatinine, median (range), mg/dL | 1.2 (0.4-1.5) | 1.2 (0.5-1.4) |
| Cirrhosis, yes/no, No. | 1618/785 | 209/122 |
| Child-Pugh classification, A/B, No. | 2159/184 | 300/31 |
| Ascites, yes/no, No. | 98/2305 | 20/311 |
| Indocyanine green retention at 15 min, ≤10%/>10%, No. | 2303/380 | 303/28 |
| Tumor size, median (range), cm | 5.5 (2.0-16.5) | 5.4 (2.0-16.0) |
| ≤3/>3 Tumors, No. | 508/1895 | 59/272 |
| Bilobar disease, yes/no, No. | 1768/635 | 258/73 |
| Extent of disease within liver, ≤50%/>50%, No. | 1530/573 | 260/71 |
| Capsule, present/absent, No. | 956/1447 | 125/206 |
| Use of sorafenib, yes/no, No. | 626/1677 | 91/240 |
SI conversions factors: To convert α-fetoprotein to μg/L, multiply by 1.0; γ-glutamyltransferase, alkaline phosphatase, aspartate aminotransferase, and alanine transaminase to μkat/L, multiply by 0.0167; total bilirubin to μmol/L, multiply by 17.104; white blood cell count to ×109/L, multiply by 0.001; hemoglobin to g/L, multiply by 10.0; platelet count to ×109/L, multiply by 1.0; and creatinine to μmol/L, multiply by 88.4.